AIM ImmunoTech Announces Emerging Ebola Opportunity for Ampligen Amid Escalating Global Health Concerns and WHO Emergency Declaration
AIM ImmunoTech announced that pre-clinical studies at USAMRIID demonstrated 100% survival in mice treated early with Ampligen against lethal Ebola virus infection. The firm plans a virtual investor presentation detailing its findings amid the WHO's declaration of Ebola outbreak as a Public Health Emergency. Ampligen, with prior Orphan Drug designat…